GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
20 mars 2023 08h45 HE
|
GeneDx Holdings Corp.
Genome Sequencing and Interpretation Services Progressing Quickly for 1,000 Newborns Enrolled in Study to Date; On Track to Support up to 100,000 Study Participants in Next Four YearsInitial Data and...
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
05 avr. 2022 08h00 HE
|
Sema4
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the...
Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
14 mars 2022 16h05 HE
|
Sema4
37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue...
Sema4 Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
08 mars 2022 08h00 HE
|
Sema4
STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, has been named to Fast Company’s prestigious annual...
Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022
22 févr. 2022 16h05 HE
|
Sema4
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine
22 févr. 2022 08h00 HE
|
Sema4
STAMFORD, Conn. and BOSTON and TORONTO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics, a...
Sema4 to Participate at Three Upcoming Investor Conferences in November
03 nov. 2021 09h15 HE
|
Sema4
STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will...
Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
19 oct. 2021 16h05 HE
|
Sema4
STAMFORD, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4 Appoints Computational Biology Expert Gustavo Stolovitzky as Chief Science Officer
13 sept. 2021 08h00 HE
|
Sema4
STAMFORD, Conn., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sema4, an AI-driven genomic and clinical data intelligence platform company, today announced the appointment of Gustavo Stolovitzky, PhD, to the...
Sema4 Launches Sema4 Elements™, a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health
09 sept. 2021 08h00 HE
|
Sema4
STAMFORD, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sema4, an AI-driven genomic and clinical data intelligence platform company, today announced the launch of Sema4 Elements™, a portfolio of...